X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (131) 131
humans (127) 127
female (98) 98
male (97) 97
middle aged (97) 97
adult (91) 91
aged (83) 83
life sciences (74) 74
hematology (72) 72
oncology (71) 71
cancer (65) 65
treatment outcome (54) 54
rituximab (45) 45
aged, 80 and over (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (38) 38
disease-free survival (38) 38
lymphoma (38) 38
lymphomas (37) 37
chemotherapy (34) 34
abridged index medicus (28) 28
adolescent (26) 26
drug administration schedule (25) 25
antineoplastic agents - therapeutic use (23) 23
therapy (23) 23
recurrence (22) 22
b-cell lymphoma (21) 21
follow-up studies (21) 21
trial (21) 21
young adult (21) 21
care and treatment (20) 20
prospective studies (19) 19
disease (18) 18
antineoplastic agents - administration & dosage (17) 17
follicular lymphoma (16) 16
kaplan-meier estimate (16) 16
antibodies, monoclonal - therapeutic use (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
chronic lymphocytic-leukemia (15) 15
doxorubicin (15) 15
neoplasm staging (15) 15
non-hodgkins-lymphoma (15) 15
survival analysis (15) 15
time factors (15) 15
cyclophosphamide (14) 14
leukemia (14) 14
lymphoma, follicular - drug therapy (14) 14
survival (14) 14
survival rate (14) 14
antibodies, monoclonal - administration & dosage (13) 13
immunology (13) 13
lymphoma, non-hodgkin - drug therapy (13) 13
prognosis (13) 13
retrospective studies (13) 13
antibodies, monoclonal, murine-derived (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
cyclophosphamide - administration & dosage (12) 12
hematology, oncology and palliative medicine (12) 12
patients (12) 12
radioimmunotherapy (12) 12
rituximab - administration & dosage (12) 12
transplantation (12) 12
antineoplastic agents (11) 11
antineoplastic agents - adverse effects (11) 11
doxorubicin - administration & dosage (11) 11
drug resistance, neoplasm (11) 11
elderly-patients (11) 11
expression (11) 11
follow-up (11) 11
phase-ii (11) 11
remission induction (11) 11
[ sdv.can ] life sciences [q-bio]/cancer (10) 10
antibodies, monoclonal, murine-derived - administration & dosage (10) 10
cyclophosphamide - therapeutic use (10) 10
doxorubicin - therapeutic use (10) 10
hodgkin disease - therapy (10) 10
leukemia, lymphocytic, chronic, b-cell - drug therapy (10) 10
lymphoma, b-cell - drug therapy (10) 10
lymphoma, large b-cell, diffuse - drug therapy (10) 10
neoplasm recurrence, local - drug therapy (10) 10
prednisone (10) 10
prednisone - administration & dosage (10) 10
response criteria (10) 10
risk factors (10) 10
vincristine (10) 10
vincristine - administration & dosage (10) 10
analysis (9) 9
animals (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
antibodies, monoclonal, murine-derived - therapeutic use (9) 9
b-lymphocytes - drug effects (9) 9
dose-response relationship, drug (9) 9
france (9) 9
hematopoietic stem cell transplantation (9) 9
hodgkin disease - drug therapy (9) 9
hodgkin disease - pathology (9) 9
lymphoma, follicular - pathology (9) 9
mantle cell lymphoma (9) 9
multicenter (9) 9
neutropenia (9) 9
non-hodgkin lymphoma (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Index Medicus | Abridged Index Medicus | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 704 - 715
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Summary Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of transplant recipients and can be Epstein–Barr virus (EBV)... 
Hematology, Oncology and Palliative Medicine | SOLID-ORGAN TRANSPLANTATION | DISTINCT ENTITY | VIRAL LOAD | ONCOLOGY | IMMUNOSUPPRESSION | DISEASE | LYMPHOMA | SINGLE-CENTER | II TRIAL | RECIPIENTS | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Index Medicus | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall... 
TRIAL | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | IMMUNOCHEMOTHERAPY | NORDIC MCL2 | FOLLOW-UP | HIGH-DOSE CYTARABINE | PHASE-3 | INTERGROUP | MCL YOUNGER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Immunologic Factors - administration & dosage | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Lymphoma, Mantle-Cell - drug therapy | Male | Transplantation, Autologous | Combined Modality Therapy | Cytarabine - administration & dosage | Cisplatin - administration & dosage | Lymphoma, Mantle-Cell - mortality | Rituximab - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Care and treatment | Usage | Patient outcomes | Mantle cell lymphoma | Stem cells | Outcome and process assessment (Health Care) | Reports | Transplantation | Observations | Medical research | Autografts | Dexamethasone | Cell survival | Hypersensitivity | Stem cell transplantation | Rituximab | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | Cytarabine | Platinum | Lymphomas | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article